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The programmed formation of specific tissues from em-
bryonic stem cells is a major goal of regenerative medi-
cine. To identify points of intervention in cardiac tissue
formation, we performed an siRNA screen in murine em-
bryonic stem cells to identify ubiquitin system genes that
repress cardiovascular tissue formation. Our screen un-
covered an F-box protein, Fbxl16, as a repressor of one of
the earliest steps in the cardiogenic lineage: FLK1 pro-
genitor formation. Whereas F-box proteins typically form
SCF ubiquitin ligases, shotgun mass spectrometry re-
vealed that FBXL16 instead binds protein phosphatase 2A
(PP2A) containing a B55 specificity subunit (PP2AB55).
Phosphoproteomic analyses indicate that FBXL16 nega-
tively regulates phosphorylation of the established
PP2AB55 substrate, vimentin. We suggest that FBXL16
negatively regulates the activity of B55-PP2A to modu-
late the genesis of FLK1 progenitor cells. Molecular &
Cellular Proteomics 13: 10.1074/mcp.M113.031765, 780–
791, 2014.
Recent attention has been directed toward understanding
how embryonic stem cell (ESC)1 differentiation in vitro can be
manipulated to generate large quantities of specific cell types
for the repair of damaged tissues, such as myocardium (1, 2).
Though the field of stem cell biology has recently made sig-
nificant advances in this direction, it has become clear that a
complex interplay of multiple signaling networks guides stem
cell fate, and thus it will be necessary to develop a deeper
understanding of how ESC signaling networks are deployed
during differentiation to harness the full therapeutic potential
of ESCs (3).
A less well-characterized example of a cellular network that
governs ESC biology and differentiation is the ubiquitin-pro-
teasome system (UPS), which constitutes a major mechanism
for the post-translational regulation of protein function and
stability in all eukaryotic cells. For example, ubiquitination of
H2A by RING1/RNF2, a core member of the polycomb re-
pressive complex, has been shown to contribute to the stable
maintenance of ESC identity (4, 5). The UPS plays a critical
role in numerous regulatory pathways that are germane to
stem cell biology, including those involved in cell proliferation,
cell differentiation, and cell death. We hypothesized that crit-
ical regulatory switches modulated by the UPS are likely to
exist in the complex molecular choreography that enables an
ESC to differentiate into a broad range of target cell types. By
analogy to DNA damage signaling by p53, hypoxia signaling
by HIF-1, and WNT signaling by -catenin, these might
involve the selective stabilization and accumulation of tran-
scription factors or other molecules that specify cell fate (6–9).
For example, consider hypoxic signaling by HIF-1. In oxy-
genated cells, HIF-1 is hydroxylated on proline, which spec-
ifies binding to a ubiquitin ligase, leading to its continuous,
rapid turnover. However, upon oxygen starvation, HIF-1 is
not ubiquitinated and degraded but accumulates to switch on
a battery of genes that reprogram metabolism and promote
the formation of blood vessels. We sought to test whether
constitutive degradation of a cardiogenic factor restricts car-
diogenesis in ESCs by screening for components of the UPS
that, upon their depletion by siRNA, lead to excess differen-
tiation of ESCs into cardiovascular progenitor cells. Although
this process occurs spontaneously in ESCs that have been
cultured in the absence of leukemia inhibitory factor, normally
only a very small fraction of ESCs convert into cardiovascular
tissue (1). This limits the potential usefulness of ESCs or
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induced pluripotent stem cells to generate cells such as car-
diomyocytes for the repair of damaged heart muscle. The
results of the studies outlined here implicate the F-box protein
FBXL16 as a repressor of cardiovascular progenitor cell
differentiation.
F-box proteins are best known for their role as substrate
receptors of SCF ubiquitin ligases (10). However, a few ex-
amples of F-box proteins that do not assemble into SCF
ubiquitin ligases have been described. Yeast RCY1 forms a
complex with SKP1 that modulates endosome to Golgi trans-
port but does not assemble with yeast CUL1 (11). In human
cells, it has been reported that FBXO45 associates with PAM,
a ring-finger ubiquitin ligase, rather than forming an SCF
complex (12). However, whether FBXO45 forms an SCF com-
plex remains controversial, given that degradation of the
FBXO45 substrate p73 is dependent on CUL1 (13), and we
identified FBXO45 as a CUL1-binding protein (14). Here we
identify FBXL16 as a mammalian F-box protein that does not
appear to assemble into an SCF ubiquitin ligase. Instead,
FBXL16 was found to bind and regulate the function of protein
phosphatase 2A (PP2A), a heterotrimeric serine phosphatase
that has diverse biological functions including modulation of
TGF signaling and cell cycle control (15). Our findings un-
cover both a putative regulator of PP2A and an unexpected
noncanonical function for an F-box protein, and they may
enable the development of cell-based therapies for the repair
of damaged myocardium.
EXPERIMENTAL PROCEDURES
Screen Design—Mouse ESCs expressing GFP under the control of
the MHC promoter (16) were plated in all wells of gelatin-coated 384
multiwell plates, and each well (except for the outside two rows and
columns around the perimeter, to minimize edge effects) was treated
with a pool of four siRNAs (Qiagen, Valencia, CA) targeting a single
member of the UPS. The total area of GFP expression (a metric for
cardiomyocyte differentiation for this cell line) was then measured via
automated microscopy on a Molecular Devices ImageXpress Auto-
mated Acquisition and Analysis System after the ESCs had been
allowed to differentiate for 12 days. All siRNA pools were tested in
duplicate wells that were located in different regions of the same
plate. The threshold for classifying an siRNA as a positive hit was that
GFP expression in each of the duplicate wells had to exceed that seen
for control luciferase siRNA-treated wells as well as the mean GFP
expression observed for the respective plate by 2 standard devia-
tions (S.D.). We also considered candidates when one duplicate
exceeded the comparators by 3 S.D. and the other by 1 S.D.
Positive hits were subject to a secondary screen that employed the
individual siRNAs constituting the active pools from the primary
screen.
Cell Culture—MHC-GFP reporter ESCs, DTC26 (kindly provided
by Dr. Richard Lee (16)), were propagated on 0.1% gelatin coated
plates in ESC medium consisting of high-glucose Dulbecco’s modi-
fied essential medium supplemented with 15% ESC qualified FCS,
leukemia inhibitory factor (Chemicon, Temecula, CA), L-glutamine,
sodium pyruvate, nonessential amino acids, -mercaptoethanol, and
Pen/Strep. For the preliminary screen these cells were placed on
75-cm2 collagen IV-coated flasks (BD Biocoat, San Jose, CA) at 4
million cells per flask for 4 days in minimum essential medium 
containing 10% FCS (as well as other components of ESC medium,
with the exception of leukemia inhibitory factor) prior to being replated
on 0.1% gelatin coated clear 384-well plates (Greiner, Monroe, NC)
at a density of 5625 cells per well in differentiation medium and
subsequently treated with siRNA. Differentiation medium consisted of
phenol-red free high-glucose Dulbecco’s modified essential medium
supplemented with 15% FCS (lot tested from Hyclone to be permis-
sive for cardiomyocyte differentiation in vitro), L-glutamine, sodium
pyruvate, nonessential amino acids, -mercaptoethanol, and 0.5 mM
ascorbic acid. The medium was changed in each well 48 h after siRNA
treatment and daily thereafter.
FLK-GFP reporter ESCs, DTC29 (kindly provided by Janet Rossant
(17)), were propagated in ESC medium as described above, but in the
presence of a feeder cell layer. Differentiation of the FLK1-GFP ESC
line was performed on collagen IV-coated six-well plates (BD Biocoat)
at a density of 800,000 cells per well in medium consisting of Dul-
becco’s modified essential medium/F12 medium, 2% ESC qualified
FCS (Hyclone), B27 supplement (Invitrogen, Logan, UT), 10 ng/ml
receptor grade EGF (Millipore, Billerica, MA), L-glutamine, sodium
pyruvate, nonessential amino acids, and -mercaptoethanol.
Mouse 3T3 and human 293 cells were propagated in Dulbecco’s
modified essential medium supplemented with 10% FCS, L-gluta-
mine, and Pen/Strep. Retrovirus packaging and infection were carried
out as described elsewhere (18). Sequences encoding the myc
epitope were fused to the 5 end of the coding sequence of Fbxl16
cDNA (Open Biosystems clone ID 40130660), and retrovirus encoding
myc-FBXL16 was then used to infect 3T3 cells to generate the stably
expressing DTC 113 line.
Nanog reporter ESCs were kindly provided by Dr. Michael Elowitz,
California Institute of Technology, Pasadena, CA.
siRNAs, Plasmids, and Transfection—The siRNA library was pur-
chased from Qiagen and transfected at 100 nM. Product numbers and
targeted gene sequence information for all siRNAs used in screening
are included in supplemental Table S1. Luciferase (control) siRNA was
purchased from Dharmacon (catalog number D-002050–01-20). Oct4
siRNA was purchased from Invitrogen (Stealth RNAi catalog number
16111296, NM 013633). Dharmafect I transfection reagent was
used for all siRNA transfections (Dharmacon, Lafayette, CO). Cells
were in siRNA containing medium for 48 h, but on the day after
transfection an equal volume of serum-containing medium was
added to each culture to maintain proper growth conditions for ESCs.
siRNA transfections directed against more than one gene utilized a
100 nM final concentration per gene targeted.
Manufacturer protocols for the Fugene 6 transfection reagent were
used in transfecting 293 and mouse ESCs. Mouse ESCs were trans-
fected for two consecutive days to enhance transfection efficiency.
Lysates were made from cells harvested 48 h after the initial trans-
fection. The HA-B55 expression vector (RDB 2691) was obtained
from Dr. Xuan Liu at the University of California Riverside. The myc-
SKP2 expression vector (RDB 2692) was obtained from Dr. Dieter
Wolf, Sanford Burnham Institute, San Diego, CA. The myc-FBXL16
expression vector (RDB 2690) was constructed by cloning the full-
length murine cDNA sequence into the MSCV vector. Sequences
encoding a single myc epitope were appended to the 5 end of the
open reading frame.
Cell Death and Proliferation Assessments—Caspase 3,7 activity
was measured using the standard manufacturer protocol for the
Promega chemiluminscent Caspase 3,7 activity assay (catalog num-
ber G8090) in ESC cultures 3 days after siRNA treatment. Results
were normalized to the signal obtained from luciferase siRNA-treated
controls. Brdu incorporation into control 3T3 cells was quantitatively
measured using the standard manufacturer protocol for the Roche
cell proliferation ELISA chemiluminescent assay (catalog number
11669915001) in 3T3 cells after treatment with Fbxl16 siRNA. Alkaline
phosphatase activity was measured 4 days after siRNA treatment of
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mouse ESCs using the Millipore quantitative colorimetric assay kit
(catalog number SCR066) per the manufacturer’s protocol. Propidium
iodide staining was performed on ESCs 3 days after siRNA treatment.
After harvesting and washing in PBS, cells were resuspended in
propidium iodide buffer (0.05 mg/ml propidium iodide, 0.1% sodium
citrate, and 0.1% TritonX-100) and treated with DNase free RNase at
a concentration of 0.2 mg/ml for 30 min. Samples were then analyzed
by means of flow cytometry to assess cell cycle status.
Immunoblotting—Whole cell lysates were normalized to 50 g of
total protein content per well as quantified by BCA (Pierce). For
cytoplasmic and nuclear extract preparation, NE-PER extraction re-
agent (Thermo) was used according to the manufacturer’s recom-
mendation. Samples loaded on 10% denaturing polyacrylamide gels
for SDS-PAGE were transferred to nitrocellulose membranes. Stand-
ard protocols were then implemented for membrane blocking, incu-
bation with antibodies, and detection with ECL reagent. Primary
antibodies used in this study included anti-myc, clone 9E10 (Cova-
nce, San Diego, CA, catalog number AFC-150P-1000), anti-Scirr1
rabbit polyclonal (Millipore, Billerica, MA, catalog number AB10223),
anti-SKP1 mouse monoclonal (Invitrogen, Carlsbad, CA, catalog
number 323800), anti-CUL1 mouse monoclonal (Invitrogen, catalog
number 322400), anti-HA rabbit polyclonal (Santa Cruz Biotechnol-
ogy, Dallas, TX, catalog number sc-805), anti-OCT4 mouse monoclo-
nal (Santa Cruz Biotechnology, catalog number sc-5279), anti-
NANOG rabbit polyclonal (Bethyl Labs, Montgomery, TX, catalog
number A300–398A), anti-PP2A-A subunit goat polyclonal (Santa
Cruz Biotechnology, catalog number sc-6112), anti-PP2A-B55
mouse monoclonal (Santa Cruz Biotechnology, catalog number
sc-81606), anti-PP2A-C subunit clone 1D6 (Millipore, catalog num-
ber 05–421), anti-phospho-Vimentin Ser56 (Cell Signaling Technol-
ogy, Danvers, MA, catalog number 3877), anti-Tubulin mouse
monoclonal (Sigma, catalog number T5168), anti-Actin mouse
monoclonal (Sigma, catalog number A3853), and anti-SP1 rabbit
polyclonal (Santa Cruz Biotechnology, catalog number sc-14027).
All primary antibodies were used at a dilution of 1:500.
RT-PCR—Total RNA was extracted from tissues using the RNeasy
RNA extraction kit (Qiagen) per the manufacturer’s protocol. One
microgram of total RNA was used for first strand cDNA synthesis
using the SuperScript III kit (Invitrogen). cDNA was used as a template
for amplification of the respective messenger RNA. HotStarTaq DNA
polymerase (Qiagen) PCR was carried out with an initial activation
step at 94 °C for 5 min followed by denaturing at 94 °C for 30 s,
annealing at 54 °C for 45 s, and extension at 72 °C for 30 s for a total
of 28 cycles (Fbxl16, GAPDH), 30 cycles (Flk1), or 33 cycles (Nkx2.5
and Isl1).
Primer sequences used for amplification of mouse messages were
as follows:
Fbxl16: forward, gtgctggacaggtgtgtacg; reverse, ctcctccagctcttg-
cagtt.
Flk1: forward, tctgtggttctgcgtggaga; reverse, gtatcatttccaaccaccc.
Nkx2.5: forward, caagtgctctcctgctttcc; reverse, ggctttgtccagctc-
cact.
Is1: forward, acgtgctttgttagggatgg; reverse, ggctacacagcggaaa-
cact.
GAPDH: forward, ggctcatgaccacagtc; reverse, tcatacttggcag-
gtttctc.
PCR products were run on a 1.5% agarose gel with ethidium
bromide.
Flow Cytometry—Differentiating ESCs were harvested by means of
trypsinization followed by resuspension in serum containing medium
and plating on a 0.1% gelatin-coated 10-cm tissue culture plate for 30
min to facilitate the removal of feeder cells. At 30 min, medium and
nonadherent cells were carefully removed from the plate, harvested
via centrifugation, and subsequently resuspended in Hanks Buffered
Saline containing 60 g/ml DNAseI, 0.6 mM magnesium sulfate, 10
mM HEPES pH 7.4, and 2.5 mg/ml BSA prior to analysis for GFP
expression. 7AAD viability dye staining (Beckman Coulter) was per-
formed to exclude dead cells from analysis, and c-KIT staining was
performed with an APC-conjugated c-KIT antibody (eBioscience, San
Diego, CA, catalog number 17–1171-81). Total cell counts prior to
analysis were obtained using a hemocytometer. Cells were sorted on
a FACSAria and analyzed on a FACSCalibur (Becton Dickinson Im-
munocytometry Systems). Data were acquired and analyzed with
Diva software (Becton Dickinson Immunocytometry Systems).
Mass Spectrometry of Immunoprecipitated Proteins—Whole cell
extracts for standard mass spectrometry analysis were prepared with
lysis buffer containing 0.2% n-dodecyl--D maltoside (Thermo) in 50
mM HEPES pH 7.5, 70 mM KOAc, 5 mM Mg(OAc)2 with complete
EDTA-free protease inhibitor mixture (Roche). After cells had been
resuspended in lysate buffer, they were placed on a nutator at 4 °C for
30 min. Lysates were then clarified via centrifugation at 4 °C and
incubated with antibody-bound magnetic beads from the Miltenyi
Biotec, Auburn, CA, tagged protein isolation kit. Immunoprecipitates
were then eluted from the magnetic column using 10 M freshly pre-
pared urea in 0.1 M Tris-HCl pH 8.5.
For subsequent mass spectrometry, the eluate was subject to an
overnight tryptic digest using standard protocols, and lyophilized
peptides were resuspended in 0.2% formic acid (14). Mass spectro-
metric analysis was carried out using the following conditions: the
mass spectrometer was a hybrid LTQ-FT-Ultra (Thermo Scientific),
and a 120-min gradient from 5% to 35% acetonitrile in 0.2% formic
acid was utilized. Survey full-scan mass spectra were acquired from
400–1600 m/z, with a resolution of 50,000 at 400 m/z. The top 10
most intense ions from the survey scan were isolated and, after the
accumulation of 5000 ions, fragmented in the linear ion trap by
collision-induced dissociation with an isolation width of 3 Th. The
dynamic exclusion list was set with a maximum retention time of 60 s,
and preview scan mode was enabled.
Global Peptide and Protein Identification—Thermo RAW files were
converted to MGF files using ReAdW4Mascot (v. 20090305a). The
MGF files were searched using Mascot (v. 2.2.06). The 293 cell data
were searched against the IPI human database v. 3.54, with 75,688
target sequences (including 262 common contaminants) and an equal
number of decoy protein sequences. The mouse ESC data were
searched against the IPI mouse database v. 3.54, with 56,246 target
sequences (including 262 common contaminants) and an equal num-
ber of decoy protein sequences. Enzyme specificity was set to fully
tryptic with up to two missed cleavages. Carbamidomethylation of
cysteine (57.0215 Da) was specified as a fixed modification. Vari-
able modifications included oxidation of methionine (15.9949 Da, 293
cells and ESCs) and carbamylation of all peptide N termini (43.0058
Da, ESCs). The precursor mass tolerance was set to 10 ppm, and the
fragment ion tolerance was set to 0.5 Da. Mascot results were loaded
in Scaffold (v. 3.6.4, Proteome Software Inc., Portland, OR), and filters
of 90% peptide probability, a minimum of two peptides, and 90%
protein probability were employed. Scaffold estimated the false dis-
covery rate as less than 1% at both the peptide and the protein level
using a target decoy rate estimate.
Sample Preparation for Phosphoproteome Analysis—For global
phospho-proteomic analysis, cells were lysed in ice-cold 8 M urea, 40
mM NaCl, 50 mM Tris (pH 8), 2 mM MgCl2, 50 mM NaF, 50 mM
-glycerophosphate, 1 mM sodium orthovanadate, 10 mM sodium
pyrophosphate, 1X mini EDTA-free protease inhibitor (Roche Diag-
nostics), and 1X phosSTOP phosphatase inhibitor (Roche Diagnos-
tics). To solubilize protein and ensure complete lysis, samples were
sonicated three times for 15 s with 30-s pauses. Approximately 5 
107 cells were processed for each condition. Total protein was then
quantified using a BCA protein assay kit (Thermo Scientific Pierce),
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reduced by DTT added to a final concentration of 5 mM, and alkylated
with 10 mM iodoacetamide. Digestion was carried out by LysC (Wako
Chemicals, Richmond, VA) added at a 1:100 enzyme-to-protein ratio
and incubation at 37 °C for 2 h. At this time, the lysate was diluted
with 50 mM Tris (pH 8) to a final urea concentration of 1.5 M and further
digested for 12 h at 37 °C with trypsin (Promega, Madison, WI) at a
1:100 enzyme to protein ratio. Peptides were then acidified with TFA
to quench the reaction and desalted using C-18 solid phase extrac-
tion columns (Waters, Etten-Leur, The Netherlands). Tandem mass
tag (TMT) or iTRAQ labeling was carried out per the manufacturer’s
directions (TMT, Thermo Scientific Pierce; iTRAQ, Applied Biosys-
tems, Foster City, CA). To confirm BCA measurements, aliquots of
total protein were taken from each sample, combined in a 1:1:1:1:1:1
ratio, and analyzed via mass spectrometry. Summed reporter ion
ratios from this experiment were used to adjust mixing ratios of the
remaining labeled digests, after which the mixed samples were again
desalted using solid phase extraction.
Peptide Fractionation—Strong cation exchange was carried out
using a polysulfoethylaspartamide column (9.4 200 mm; PolyLC) on
a Surveyor LC quaternary pump (Thermo Scientific; flow rate of 3.0
ml/min). The following gradient was used for separation: 0–2 min,
100% buffer A; 2–5 min, 0%–15% buffer B; 5–35 min, 15%–100%
buffer B. Buffer B was held at 100% for 10 min. The column was
washed extensively with buffer C and water prior to recalibration.
Buffers were as follows: buffer A (5 mM KH2PO4, 30% acetonitrile (pH
2.65)), buffer B (5 mM KH2PO4, 30% acetonitrile, 350 mM KCl (pH
2.65)), buffer C (50 mM KH2PO4, 500 mM KCl (pH 7.5)). Samples were
collected by hand and desalted via solid phase extraction.
Phosphopeptide Enrichment—Phosphopeptides were enriched
from each fraction of the polysulfoethylaspartamide column via im-
mobilized metal affinity chromatography using magnetic beads (Qia-
gen). Following equilibration with water, the beads were treated with
40 mM EDTA (pH 8.0) for 30 min with shaking and washed three times
with water. The beads were then incubated with 100 mM FeCl3 for 30
min with shaking and finally were washed three times with 80%
acetonitrile/0.15% TFA. Samples were resuspended in 80% acetoni-
trile/0.15% TFA and incubated with beads for 45 min with shaking.
The resultant mixture was washed four times with 1 ml 80% aceto-
nitrile/0.15% TFA and eluted using 1:1 acetonitrile:0.7% NH4OH in
water. Eluted phosphopeptides were acidified immediately with 4%
formic acid and lyophilized to 5 l.
Mass Spectrometry of Phosphopeptides—Data collection was per-
formed using an ETD-enabled Velos-Orbitrap (Thermo Fisher Scien-
tific). Online reverse-phase chromatography was carried out using a
NanoAcquity UPLC system (Waters). Peptides were loaded onto a
precolumn (75-m inner diameter, packed with 5-cm C18 particles;
Alltech, Deerfield, IL) for 10 min at a flow rate of 1 m/min. Samples
were then eluted over an analytical column (50-m inner diameter,
packed with 15-cm C18 particles; Alltech) using a 120-min linear
gradient from 2% to 35% acetonitrile with 0.2% formic acid and a
flow rate of 300 nl/min. Data-dependent top-ten sampling methods
were used consisting of one MS1 scan (resolving power  30,000–
60,000) followed by data-dependent Quantmode scans (resolving
power  7500). Quantmode, a recently described gas phase purifica-
tion method, improves the quantitative accuracy of isobaric labeling by
separating the target peptide from interfering peptides (19). In each
Quantmode scan, gas phase purification was followed by beam-type
collision-activated dissociation (higher-energy collision-activated disso-
cation) to generate reporter tags which were then mixed with a subse-
quent collision-activated dissociation fragmentation of the precursor
ion. Both populations were then simultaneously analyzed in the Or-
bitrap. Dynamic exclusion was set for 30 to 45 s using a window of
0.55 Th to 2.55 Th. Precursors with unassigned charge states or
charge states of 1 were excluded from analysis. Automatic gain control
target values were 1,000,000 for MS1 analysis and 100,000 for Quant-
mode MS2 analysis. Raw data files are available at ChorusProject.
org under the project name “FBXL 16 regulated PP2A-B55alpha” or via
the following links: https://chorusproject.org/anonymous/download/
experiment/-6588121327762421312 and https://chorusproject.org/
anonymous/download/experiment/3463894323331911718. Mass-
labeled annotated spectra for all one-peptide protein identifica-
tions, as well as all post-translational modifications containing pep-
tide spectrum matches, can be found online with the supplemental
data.
Database Searching and False Discovery Rate Estimation—MS/MS
data were analyzed using the Coon OMSSA Proteomics Software
Suite (COMPASS) (20). The Open Mass Spectrometry Search Algo-
rithm (OMSSA; version 2.1.4) was used to search spectra against
peptides resulting from an in silico trypsin digest (allowing three
missed cleavages) of the IPI mouse database (v. 3.79) (21, 22). The
precursor mass tolerance was set to 	4.5 Da and the monoisotopic
mass tolerance was set to 	0.015 Da for fragment ions. Large pre-
cursor mass tolerance coupled with post-search filtering based on
precursor mass, such as the algorithm employed in FDROptimizer,
has been demonstrated to increase the number of peptide identifica-
tions (23). Carbamidomethylation of cysteines, TMT on the N termi-
nus, and TMT on lysines were included as fixed modifications, and
oxidation of methionines and TMT on tyrosines were set as variable
modifications. Results were filtered to a 1% false discovery rate at
both the peptide and the protein level (24).
Protein and Peptide Quantification—TMT or iTRAQ quantification
was performed using TagQuant within COMPASS (20) This program
extracts reporter ion intensities and multiplies them by injection times
to determine counts. Purity correction was performed as previously
described (25). Tag intensities were normalized to ensure that the
total signal from each channel was equal. Reporter ion intensities for
each channel were summed for all peptides in a given protein with
two exceptions: (i) scans corresponding to peptides found in multiple
protein groups were not used for quantification, and (ii) peptides
found to be phosphorylated were not used for protein quantification.
Phosphorylation Analysis—Phosphopeptides were filtered to a 1%
false discovery rate based on unique peptides. To ensure accurate
reporting, phosphorylated peptides and nonphosphorylated peptides
were grouped into proteins following previously established criteria
(24). The Phosphinator software was used to localize phosphorylation
sites to a 95% confidence level (26). Quantitative information from all
phosphopeptides with the same sites was summed to achieve accu-
rate quantification for each site.
In screening for differentially phosphorylated peptides, a 1.5-fold
difference in phosphorylation between samples (in comparison to
control) was used to identify candidates of interest. If these candi-
dates satisfied our metric for statistical significance—p 
 0.05 and
q 
 0.05 with initial analysis in 3T3 and mouse ESCs, as well as p 

0.05 and q 
 0.2 after analysis to adjust for protein normalization in
mouse ESCs—the candidate peptide was considered as differentially
phosphorylated.
Recombinant Protein Expression—Full-length Fbxl16 cDNA was
cloned into the SKP2-SKP1 pGEX expression vector in place of the
SKP2 coding sequence to yield RDB 2693. FBXL16-SKP1 was puri-
fied from E. coli as described elsewhere (27).
Serine/Threonine Phosphatase Activity—Both HA-tagged B55-
associated PP2A and myc-FBXL16 associated PP2A were immuno-
precipitated using the Miltenyi Biotec protein tag purification kit as
described above. Immunoprecipitated holoenzyme was eluted from
the magnetic bead column by removing the column from the mag-
netic stand and adding buffer that contained 20 mM Tris-HCl pH 8.0,
5 mM MgCl2, 100 mM KCl, 0.2 mM EDTA, 0.25 mM AEBSF, 10%
glycerol, and 0.2% n-dodecyl--D maltoside. The enzyme was then
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assayed directly for phosphatase activity using the phosphothreonine
hexa-peptide, malachite green, and assay buffer from a commercially
available kit per the manufacturer’s protocol (Millipore, catalog num-
ber 17–313). For experiments using -catenin and cyclin-E phospho-
peptides, a final phosphopeptide concentration of 188 M was used
in each reaction (including control phosphopeptide) (27, 28).
RESULTS
Fbxl16 Restrains FLK1 Cell Differentiation—To identify
candidate UPS genes that repress the differentiation of ESCs
into cardiovascular tissue, we utilized mouse ESCs that ex-
press GFP under the control of the cardiac-specific promoter
for -myosin heavy chain (16). Briefly, ESCs were plated on
384-well plates under conditions permissive for differentia-
tion, transfected in duplicate with pools of siRNA from a
custom siRNA library directed toward components of the
murine UPS (supplemental Table S1), and imaged 12 days
later using an automated epifluorescence microscope to iden-
tify wells that exhibited enhanced formation of GFP-positive
cardiomyocytes.
Results of the primary screen suggested that siRNA pools
that target several mRNAs including Fbxl16 promoted differ-
entiation into cardiomyocytes (supplemental Fig. S1). Be-
cause Fbxl16 was the only target for which all four siRNAs in
the pool promoted cardiomyocyte differentiation, we selected
it for further investigation. Knockdown of Fbxl16 mRNA was
confirmed by RT-PCR analysis of ESC cultures following
treatment with these siRNAs (supplemental Fig. S2A). Knock-
down of FBXL16 protein was also observed in 3T3 cells
engineered to stably overexpress myc-tagged FBXL16 (myc-
FBXL16; supplemental Fig. S2B).
Because the siRNA treatment was performed at the onset
of differentiation, we reasoned that FBXL16 might be repress-
ing early steps in the cardiac lineage. To test this hypothesis,
we evaluated the differentiation of a second mouse ESC line
that expresses GFP under the control of the promoter for Flk1,
a well-established marker for cardiovascular progenitor cells
(17, 29). When these cells were treated with Fbxl16 siRNA we
observed a significant increase in the total number and pro-
portion of GFP (i.e. FLK1) cells as assessed by flow cy-
tometry (Figs. 1A and 1B). Similar results were obtained with
a second siRNA that targets a distinct sequence in Fbxl16
(supplemental Fig. S2C). Because FLK1 expression occurs in
a variety of cell types, including endothelial cells, the GFP
population was then assessed for co-expression of other
markers for cardiovascular progenitor cells including Nkx2.5
and Isl-1mRNAs and c-KIT protein (1, 2). The expression of all
three markers was elevated in GFP cells isolated from cul-
tures treated with Fbxl16 siRNA, suggesting that the cell
population being studied included cardiovascular progenitors
(Figs. 1C and 1D). Given that the depletion of Fbxl16 en-
hanced the formation of FLK1 cells, we sought to test
whether overexpression of Fbxl16 might have the converse
effect. However, though transient transfections had limited
success, attempts to stably overexpress Fbxl16 in ESCs by
means of either transfection or viral transduction were unsuc-
cessful due to reduced ESC clone viability.
In addition to increasing both the proportion and the total
number of FLK1 cells in culture, Fbxl16 knockdown reduced
the total number of cells with a concomitant increase in non-
viable, nonadherent cells (supplemental Figs. S2D and S2E).
This effect was not due to perturbation of the cell cycle, as
assessed by propidium iodide staining or BrdU labeling (sup-
plemental Figs. S2F and S2G). However, caspase 3,7 activity
was significantly increased in siRNA-treated cultures (supple-
mental Fig. S2H). This suggests that the reduction in cell
number was due to apoptosis.
Because Fbxl16 suppression resulted in an apparent in-
crease in the differentiation of ESCs to FLK1 cells, we asked
whether the effect was due to an overall loss of stem cell
identity. To evaluate this possibility, we examined a number of
different markers for stem cell identity (30) in cultures treated
FIG. 1. Fbxl16 represses an early event in the cardiogenic line-
age. A, B, increased percentage and total number of FLK1 cells in
differentiating ESC cultures upon silencing of Fbxl16. Differentiating
ESCs that contain a GFP reporter knocked into one of the two Flk1
loci were harvested 4 days after treatment with the indicated siRNA.
Quantification of the GFP signal (used as a surrogate for FLK1) was
performed via flow cytometry, and either the percentage (A) or the
total number (relative to luciferase control) (B) of GFP-positive cells is
reported. Error bars represent 	1 S.D. C, co-expression of cardio-
vascular markers in Fbxl16-depleted cells. Sorted FLK1 (GFP-pos-
itive) cells were subjected to semiquantitative RT-PCR to evaluate
mRNAs that encode the cardiovascular progenitor markers FLK1,
NKX2.5, and ISL1. GAPDH message is shown as a control. D, same
as A and B, except that c-KIT was evaluated via antibody staining.
The graph shows the total number (relative to luciferase control) of
FLK1 and c-KIT double positive cardiovascular progenitor cells in
culture after treatment with the indicated siRNA (the mean of two
separate experiments is shown; both experiments demonstrated sim-
ilar results with S.D.  0.122 calculated for Fbxl16 siRNA-treated
cells).
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with control (luciferase) versus Fbxl16 siRNA (supplemental
Fig. S2I). To rule out potential artifacts that might arise from
population averaging, we evaluated NANOG expression in
single cells by employing murine ESCs that express a
NANOG-CFP reporter. FACS analysis of the NANOG-CFP
cells revealed little or no loss of NANOG-positive cells in
cultures depleted of Fbxl16 mRNA (supplemental Fig. S2J).
By contrast, strong depletion of NANOG-positive cells was
observed upon treatment with Oct4-specific siRNA. OCT4
and NANOG protein levels were not affected in ESCs de-
pleted of Fbxl16mRNA (supplemental Fig. S2K). These results
suggest that the suppression of Fbxl16 enabled a subpopu-
lation of ESCs to differentiate into FLK1 cardiovascular pro-
genitors. Because we have not evaluated other markers, we
do not know whether depletion of Fbxl16 enhances or re-
duces differentiation along other lineages unrelated to FLK1
or enhances the formation of cell types derived from FLK1
progenitors other than cardiomyocytes.
FBXL16 Does Not Form an SCF Ubiquitin Ligase—We next
sought to understand the mechanisms by which FBXL16
functions. Given that FBXL16 is a member of the family of
F-box proteins (10) that assemble with CUL1, SKP1, and
ROC1/RBX1/HRT1 to form SCF ubiquitin ligases, we antici-
pated that FBXL16 would form an SCF ubiquitin ligase that
targets for ubiquitination and degradation a protein that pro-
motes formation of FLK1 progenitors. To test this hypothe-
sis, we constructed an expression vector that encoded a myc
epitope fused to the N terminus of full-length FBXL16 (myc-
FBXL16). As shown in Figs. 2A and 2B, myc-FBXL16 was
expressed in stably transfected 3T3 cells and localized to the
cytosolic fraction of whole cell lysate. To evaluate the assem-
bly of myc-FBXL16 into SCF complexes, we performed anti-
myc immunoprecipitation followed by immunoblotting with
antibodies against SCF subunits. As expected, myc-FBXL16
bound SKP1 (Fig. 2C). This interaction was direct because it
could be reconstituted with recombinant FBXL16 and SKP1
FIG. 2. FBXL16 is a cytoplasmic protein that binds SKP1 and PP2A but does not bind CUL1. A, expression of myc-FBXL16. Total cell
lysate was prepared from 3T3 cells that were either mock-transfected or stably transfected with plasmids that contained the coding sequences
for either myc-SKP2 or myc-FBXL16. Lysates were evaluated via SDS-PAGE followed by immunoblot with anti-myc. B, myc-FBXL16 is a
cytosolic protein. Cytosolic (Cyt) and nuclear (Nuc) fractions prepared from 3T3 cells stably expressing myc-FBXL16 were fractionated by
means of SDS-PAGE and immunoblotted for myc-FBXL16, -actin (a cytosolic marker), and SP1 (a nuclear marker). C, myc-FBXL16 binds
SKP1 and PP2A but not CUL1. Total cell lysates from 293 cells that were either mock-transfected or transfected with plasmids that contained
the coding sequences for either myc-SKP2 or myc-FBXL16 were subjected to immunoprecipitation with anti-myc. Immunoprecipitates were
fractionated via SDS-PAGE and immunoblotted with antibodies against SKP1, CUL1, and PP2A subunit A. D, FBXL16, but not SKP2,
co-immunoprecipitates serine/threonine phosphatase activity. Total cell lysates from 293 cells that were either mock-transfected or transfected
with plasmids that contained the coding sequences for myc-SKP2, myc-FBXL16, or HA-B55 (included as a positive control) were subjected
to immunoprecipitation with either anti-myc (SKP2 and FBXL16) or anti-HA (B55). Immunoprecipitates were assayed for their content of
serine/threonine phosphatase activity. Error bars represent 	1 S.D.; n  3 for each sample.
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co-expressed in E. coli (supplemental Fig. S3A). However, to
our surprise, FBXL16 exhibited no detectable association with
CUL1. This result, though unexpected, is consistent with the
absence of FBXL16 from the repertoire of known CUL1-as-
sociated proteins (14, 31). By contrast, equivalently tagged
F-box protein SKP2 displayed a robust association with both
SKP1 and CUL1 (Fig. 2C).
FBXL16: A Novel Regulator of PP2A Holoenzyme—If
FBXL16 does not form an SCF ubiquitin ligase, we reasoned
that it must impede the formation of FLK1 cardiac progen-
itors through a distinct pathway. To investigate FBXL16’s
mechanism of action, we sought its binding partners. Shotgun
mass spectrometry of myc-FBXL16 immunoprecipitates re-
covered from 293T cells revealed multiple candidates, most of
which were also detected in either myc-SKP2 or untagged
control immunoprecipitations (supplemental Table S2, 293
Proteins tab). However, 17 proteins were found in the myc-
FBXL16 but not the untagged or myc-SKP2 samples (Table I).
Consistent with the immunblotting data, CUL1 was not found
in the myc-FBXL16 immunoprecipitate, whereas SKP1 was
readily detected. Notably, CUL1 was readily identified in a
myc-SKP2 immunoprecipitate analyzed in parallel (Table I).
Strikingly, the FBXL16-associated protein for which the
greatest number of peptides was sequenced was PP2A (Ta-
ble I). PP2A holoenzyme comprises three major subunits, all
of which were detected in myc-FBXL16 immunoprecipitates:
a catalytic C subunit, a regulatory A subunit, and one of 13
different B subunits that confer substrate specificity (32). Only
one of these—B55 (PP2R2A)—was detected with at least
two unique peptides in the myc-FBXL16 pull-down. However,
we cannot rule out the presence of B55, B55, and B55
because one of the identified peptides is shared by all four
proteins (supplemental Table S2, PP2A subunits and 293
peptide information tabs). Specific association of PP2A’s A
subunit with FBXL16 was corroborated by immunoblot of
myc-FBXL16 and myc-SKP2 immunoprecipitates (Fig. 2C).
Likewise, myc-FBXL16 was recovered in immunoprecipitates
of HA-tagged B55 (HA-B55) prepared from 293 cells that
TABLE I
Identification by shotgun mass spectrometry of proteins that co-immunoprecipitated with myc-FBXL16 or myc-SKP2
All unique proteins binding to FBXL16 are shown, and the top three candidate proteins bound to SKP2, as rated by the number of spectral
counts, are listed. SKP1 is included in this list because it was the only protein that demonstrated abundant associations with both FBXL16 and
SKP2, again as rated by spectral counts. None of the candidates listed are found in mock transfected 293 cells. No other PP2A subunits were
found to co-immunoprecipitate with FBXL16, and no PP2A subunits were found to co-immunoprecipitate with SKP2. Complete results are
shown in the supplementary data.
FBXL16 Regulates PP2A-B55
786 Molecular & Cellular Proteomics 13.3
overexpressed both proteins, confirming that FBXL16 can
bind B55 (supplemental Fig. S3B). PP2A holoenzyme bound
to myc-FBXL16 appeared to be functional, in that phospha-
tase activity was readily detected in myc-FBXL16 but not
myc-SKP2 immunoprecipitates (Fig. 2D). Several proteins,
including CIP2A, SET, ARPP19, and endosulfine, bind PP2A
and inhibit its activity (33–36). SET was identified in the
FBXL16 immunoprecipitate, albeit in relatively low amounts
(Table I). By contrast, none of the known PP2A subunits or
regulators was detected in the untagged control or myc-SKP2
immunoprecipitates (Table I). Importantly, association of
FBXL16 with PP2A was not unique to transformed cells, be-
cause we also recovered the A, B55, and C subunits of PP2A
in myc-FBXL16 immunoprecipitates isolated from transiently
transfected murine ESCs (supplemental Table S2, Mouse ES
proteins tab).
To test whether FBXL16 might directly regulate PP2A cat-
alytic activity, we retrieved A-B55-C heterotrimers from cells
via immunoprecipitation of transiently expressed HA-B55 or
myc-FBXL16. When these precipitates were normalized
based on their content of catalytic C subunit (Fig. 3A), we
observed no difference in phosphatase activity toward either
a generic substrate (Fig. 3B) or specific peptide substrates
(Fig. 3C), including a -catenin phosphopeptide whose phos-
phorylation sites are A-B55-C targets (37). Thus, FBXL16
does not appear to influence directly the active site of the C
subunit.
Recently, it was shown that Xenopus A-B55-C hetero-
trimer is negatively regulated by ARPP19 and endosulfine, but
only when the latter is phosphorylated by the protein kinase
Greatwall (33, 36). This suggested that our failure to detect an
effect of FBXL16 on PP2A catalytic activity could be due to
the absence of a critical regulatory modification. Alternatively,
FBXL16 might regulate PP2A via a distinct mechanism such
as localization or by modulating association with substrates,
or FBXL16 might serve exclusively as a substrate for
A-B55-C. To distinguish between these possibilities, we
sought to measure PP2A activity in the presence or absence
of FBXL16 in a more physiological context. To this end, we
performed global phosphopeptide profiling by means of
quantitative mass spectrometry (38). Parallel cultures of ESCs
were treated with either control siRNA or Fbxl16-specific
siRNA. Total cell lysates prepared from these cultures were
digested in parallel with trypsin, and the resulting peptides
were labeled with different isobaric mass tags. After the la-
beled isotopomers had been mixed, phosphopeptides were
enriched via immobilized metal affinity chromatography prior
to analysis by quantitative mass spectrometry. The identifica-
tion and relative quantification of 5600 phosphoisoforms
(including peptides for which the exact phosphorylation site
was localized and those for which the exact phosphorylation
site was not identified (i.e. unlocalized)) were achieved in this
analysis (supplemental Table S3). A plot of the distribution of
peptide abundance ratios of isoforms that were localized and
achieved both a p value of 
0.05 and a q value of 
0.05
revealed that some phosphoisoforms were increased upon
FBXL16 depletion, whereas others were diminished (Fig. 4A).
The fraction that was diminished was larger than the fraction
that was increased, implying that the net effect of FBXL16
was to antagonize a subpopulation of PP2A, such that in cells
in which FBXL16 was depleted, PP2A exhibited higher net
activity, resulting in a lower abundance of a subset of its
phosphorylated substrates. To test this idea, we performed
the same analysis, but this time we compared control cells
with cells overexpressing myc-FBXL16. We were unable to
FIG. 3. FBXL16 binding to B55-PP2A does not alter the intrin-
sic catalytic activity of the enzyme. A, relative level of PP2A cata-
lytic subunit in myc-FBXL16 and HA-B55 immunoprecipitates.
Amounts of PP2A catalytic subunit C were estimated through volu-
metric titration of HA-B55 immunoprecipitate compared with a fixed
volume of myc-FBXL16 immunoprecipitate. Samples were fraction-
ated via SDS-PAGE and immunoblotted with antibody against the C
subunit. B, robust phosphatase activity is associated with FBXL16.
The specific PP2A activity was calculated based on the amount of
catalytic subunit (A), and whole cell lysates from 293 cells transfected
with either no vector (Mock) or myc-FBXL16 or HA-B55 expression
vectors were immunoprecipitated and assayed for serine/threonine
phosphatase activity using a commercial PP2A phosphopeptide as-
say. Error bars represent 	1 S.D.; n  3 for each sample. OA 
okadaic acid, 50 nM final concentration. C, same as B, except that
phosphorylated -catenin (a known substrate of the B55 form of
PP2A) and cyclin E (not a described PP2A substrate) peptide sub-
strates were used (37). The peptide substrates employed here are the
same as those used in prior ubiquitination studies (27, 28). The
commercial PP2A peptide was used as a positive control, and mea-
surements were made in duplicate. Error bars represent 	1 S.D.
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perform this analysis in ESCs because of the limited efficiency
of transient transfections and reduced viability of ESCs stably
transfected with Fbxl16, so 3T3 cells were used instead. The
identification and relative quantification of 11,500 phospho-
isoforms (both localized and unlocalized) were achieved in
this analysis (supplemental Table S3). A plot of the distribution
of relative abundances of phosphoisoforms that were local-
ized and achieved both a p value of 
0.05 and a q value of

0.05 is shown in Fig. 4B. In contrast to the result observed
upon Fbxl16 depletion, cells that overexpressed myc-FBXL16
exhibited a modest shift toward higher net phosphorylation.
Both knockdown and overexpression studies are subject to
different types of indirect effects that could skew the levels of
individual phosphopeptides. Therefore, we reasoned that the
most robust candidates for true FBXL16-modulated PP2A
substrates would be those that exhibited reciprocal re-
sponses to FBXL16 overexpression and knockdown. Five
phosphoisoforms met this criterion (Fig. 4C). Four of the five
were increased in cells that overexpressed FBXL16 and de-
creased in cells in which FBXL16 was depleted. This sup-
ported our hypothesis that FBXL16 is a negative regulator of
a subset of PP2A complexes in vivo. Among the phosphoiso-
forms that exhibited reciprocal responses to FBXL16 over-
expression and depletion was one from the intermediate
filament protein vimentin. Notably, phospho-vimentin is a
substrate of the A-B55-C holoenzyme (39). Immunoblot-
ting with an antibody that recognizes phospho-Ser56 of
vimentin validated our mass spectrometry finding that over-
expression of myc-FBXL16 enhanced phosphorylation of
this site (Fig. 4D).
DISCUSSION
FBXL16 Is an F-box Protein That Does Not Form a Stable
SCF Complex—The hypothesis motivating the siRNA screen
reported here is that ESCs constitutively express UPS pro-
teins that restrain the formation of cardiovascular tissue by
promoting the degradation of factors that promote differenti-
ation along the cardiovascular lineage. Our screen identified
FIG. 4. Phosphoproteomic analysis reveals differentially phosphorylated proteins in response to either Fbxl16 overexpression or
suppression. A, phosphoisoform profile of Fbxl16-depleted cells. Quantitative iTRAQ mass spectrometry analysis of phosphopepetides was
performed on mouse ESCs that were treated with siRNAs directed toward either Fbxl16 or luciferase. Each bin corresponds to phosphoiso-
forms that were decreased or increased by the indicated fold amount upon treatment with Fbxl16 siRNA relative to luciferase siRNA. The y-axis
indicates the number of phosphoisoforms in each bin. The histogram is plotted to emphasize proteins that were found to be differentially
phosphorylated by at least 1.5-fold. B, phosphoisoform profile of FBXL16-overexpressing cells. Same as A, except that 3T3 cells that
contained a stably integrated control vector or myc-FBXL16 expression vector were compared. C, five candidate PP2A substrates exhibit
reciprocal responses to FBXL16 depletion and overexpression. D, validation of vimentin as an FBXL16-modulated phosphoprotein. Total
extracts of 3T3 cells stably transfected with control or myc-FBXL16-expression vector were fractionated via SDS-PAGE and immunoblotted
with the indicated antibodies. The vimentin antibody specifically recognizes phosphorylation on serine 56.
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Fbxl16 as a candidate UPS gene that represses a very early
step in the cardiovascular program: the formation of FLK1
progenitor cells. Although we set out to identify UPS proteins
that regulate cardiogenesis, our data suggest that FBXL16 is,
unexpectedly, not a component of the UPS. Whereas all
tested mammalian F-box proteins can assemble into an SCF
complex, we failed to detect the core SCF subunit CUL1 in
FBXL16 immunoprecipitates, which is consistent with prior
proteomic studies that failed to detect FBXL16 in CUL1 im-
munoprecipitates (14, 31). Note that although early studies
suggested that Fbxo5/Emi1 might not form an SCF com-
plex, we and others have identified it as a CUL1-associated
protein (14, 31, 40). It remains formally possible that FBXL16
can form an SCF complex but does so only under certain
conditions that were not reproduced in our experiments.
Though essentially all well-studied metazoan F-box proteins
form SCF complexes, yeast RCY1 and CTF13, like FBXL16,
bind to SKP1 but do not assemble with yeast CUL1 (11, 41).
Interestingly, FBXL16 does not contain a conserved proline
residue that may specify association of F-box proteins with
CUL1 (42).
FBXL16 Binds PP2AB55 Complexes—If FBXL16 does not
form a stable SCF complex, then what does it do? Our data
implicate FBXL16 in the biology of PP2A complexes, in par-
ticular those that contain a regulatory subunit of the B55
family (B55-). FBXL16 immunoprecipitates from both 293
and ESCs contain all subunits of the B55-PP2A holoenzyme.
The B55 subunit is definitely present, but the B55, B55,
and B55 subunits are ambiguous because one of the pep-
tides that was sequenced is shared by all four proteins. We
were unable to identify a single peptide from any one of the
other nine B subunit genes, but this might be due to a lower
abundance of these proteins in 293 and 3T3 cells. In addition
to PP2A holoenzyme, the 293 immunoprecipitates exhibit
phosphatase activity. This raises the question, what is the
relationship between FBXL16 and PP2A activity? We first
considered the possibility that FBXL16 is a substrate of PP2A.
However, we did not detect FBXL16 phosphorylation in a
phosphoproteome analysis. In addition, given the high ratio of
PP2A to FBXL16 peptide counts in the mass spectrometry
analysis, it seems unlikely that FBXL16 serves as a substrate.
We next considered that FBXL16 might somehow regulate
PP2A activity. FBXL16 immunoprecipitates contained robust
phosphatase activity, suggesting that FBXL16 does not di-
rectly impinge on the active site of the C subunit. Consistent
with our observation that FBXL16 does not form a ubiquitin
ligase complex that might target B55 for ubiquitin-mediated
degradation, neither depletion (supplemental Fig. S3C and
supplemental Table S3 (Suppress protein tab)) nor overpro-
duction (supplemental Table S3, Overexpress protein tab) of
FBXL16 had an effect on B55 protein levels.
Phosphoproteomic analyses of cells that were either de-
pleted of or overexpressed FBXL16 revealed five proteins that
exhibited reciprocal responses to these manipulations. In four
of the five cases, the response seen was consistent with
FBXL16 serving as a negative regulator of PP2A. One of these
five proteins, the intermediate filament protein vimentin, is a
known direct target of the PP2AB55 holoenzyme (39) and was
confirmed by immunoblotting with a phospho-specific anti-
body to exhibit increased phosphorylation on its Ser56 resi-
due upon overexpression of FBXL16. Thus, our data point to
FBXL16 as a negative regulator of vimentin dephosphor-
ylation by PP2AB55. It remains unclear whether the activity of
FBXL16 is restricted to B55-containing complexes or might
affect other B subunits that were not detected by mass spec-
trometry. In addition, it is not known whether FBXL16 im-
pedes dephosphorylation of all PP2AB55 substrates or only a
particular subset. Finally, the mechanism by which FBXL16
influences PP2AB55 activity is not known. Enzymatic assays
revealed that FBXL16 apparently does not inhibit the catalytic
site of the B55 holoenzyme. It remains possible that FBXL16
blocks the association of PP2AB55 with protein substrates or
influences the subcellular localization of the holoenzyme. Fu-
ture studies should reveal the specificity of FBXL16’s regula-
tory function and the mechanism by which it exerts its inhib-
itory effect.
FBXL16 Influences Differentiation of ESCs—Depletion of
Fbxl16 from ESCs derepresses a very early step along the
cardiomyocyte lineage, leading to increased formation of
FLK1 cells. Analysis of stem cell markers in Fbxl16-depleted
ESCs indicates that Fbxl16 is not required to maintain stem
cell identity. However, it remains untested whether Fbxl16
promotes or represses differentiation along other lineages
besides FLK1 or affects steps in the cardiomyocyte lineage
or other lineages downstream of the FLK1 progenitor. Our
identification of Fbxl16 as a negative regulator of a heterotri-
meric PP2AB55 complex implies that B55 stimulates the
formation of FLK1 cells. Although we identified vimentin as
an FBXL16-responsive phosphoprotein, the PP2AB55 ho-
loenzyme is likely to have many other substrates, and thus it
is unlikely that diminished vimentin phosphorylation by itself
accounts for the increased differentiation of ESCs to FLK1
cells upon Fbxl16 depletion. However, it is of interest to note
that vimentin has been implicated in cellular signaling path-
ways known to affect cell differentiation and has been hypoth-
esized to mediate morphological changes required by cells in
order to make such transitions (43–45). Identifying the rele-
vant step(s) and the key substrate(s) targeted by B55 will
require more in-depth analysis of factors that specify FLK1
cells.
Although we focused our attention on Fbxl16, our screen
identified other genes that may restrict the differentiation of
cardiomyocytes. Importantly, our results suggest that parallel
approaches may uncover UPS genes that influence differen-
tiation along other lineages that emerge from ESCs.
PP2A and Cancer—PP2A behaves as a tumor suppressor
(46). Most likely, this reflects its ability to counteract growth-
promoting signal transduction pathways. Multiple mecha-
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nisms restrain PP2A activity and can contribute to cellular
transformation, including viral proteins such as the small T
antigen of SV40 (47, 48) and endogenous inhibitors including
SET (35), CIP2A (34), PME-1 (49), and the closely related
ARPP19 and endosulfine proteins (33, 36). Deregulation of
SET and CIP2A has been implicated in multiple hematological
malignancies (50). Fbxl16 is up-regulated upon silencing of
either product (p16INK4A or p14ARF) of the CDKN2A locus
(51). Thus, mutation of CDKN2A in human cancer may down-
regulate the activity of PP2A complexes that contain B55.
Additionally, the Fbxl16 locus is amplified in a number of
cancers, most notably invasive breast carcinoma, where 5%
of 489 cases exhibit amplification (cBio Cancer Genomics
Portal). Given the findings reported here, it will be interesting
to see whether FBXL16 modulates PP2A activity in human
cancer.
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